Saturday 17 October 2026
Export ERAS’s income statement to Excel — free account
Erasca, Inc.
ERAS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 16.7% and free cash flow fell 4.67%, each against the same quarter a year earlier.
13.39
1.48
−9.95%
Follow ERAS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(32.00%) | (33.27%) | (69.86%) | (78.25%) | |
| (26.90%) | (27.72%) | (59.42%) | (65.25%) | ||
ROIC |
(151.31%) | (179.37%) | (122.37%) | (203.13%) | |
Return on Tangible Assets |
(44.76%) | (45.95%) | (115.55%) | (111.85%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.38) | (0.37) | (0.82) | (0.81) | |
Free Cash Flow |
(107.93) | (105.08) | (250.86) | (252.08) | |
Capital Expenditures |
(9.62) | (9.63) | (159.58) | (154.06) | |
| Other line items | |||||
Cash ROIC |
(16.96%) | (17.48%) | (39.36%) | (39.97%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.77 | 0.77 | 0.33 | 0.34 | |
Depreciation/Fixed assets |
(0.26) | (0.15) | (0.07) | 0.01 | |
Capex/Depreciation |
2.63 | 4.86 | 190.20 | (2,525.56) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.35) | (0.34) | (0.30) | (0.31) | |
Capex per Share |
(0.03) | (0.03) | (0.52) | (0.49) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates